Shuttle Pharmaceuticals Holdings, Inc.
- Open
- 4.06
- Day high
- 4.08
- Day low
- 3.90
- Prev close
- 4.10
- Volume
- 44K
- Mkt cap
- $4M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 1.2
- P/S
- —
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$323K over the last 3 months (6 open-market buys, 5 sales)
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) is a Healthcare company listed on NASDAQ. The stock is up 24% over the past year. Over the trailing 3 months, insiders filed 6 open-market buys and 5 sales (SEC Form 4).
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
SHPH earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 15, 2026 | — | $-0.43 | — | — | — |
| Nov 13, 2025 | — | $-1.05 | — | — | — |
| Aug 12, 2025 | — | $-3.29 | — | — | — |
| May 8, 2025 | — | $-7.50 | — | — | — |
| Mar 20, 2025 | — | $-0.80 | — | $5748 | — |
| Sep 3, 2024 | — | $-24.00 | — | — | — |
| Mar 21, 2024 | — | $-20.00 | — | $9656 | — |
| Nov 13, 2023 | — | $-0.11 | — | — | — |
| Aug 14, 2023 | — | $-0.15 | — | — | — |
| May 25, 2023 | — | $0.02 | — | — | — |
| Mar 15, 2023 | — | $-0.06 | — | — | — |
| Nov 14, 2022 | — | $-0.10 | — | — | — |
SHPH insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 15, 2026 | HRT FINANCIAL LP10 percent owner | Sell | 82,116 | $4.48 |
| Jul 15, 2026 | HRT FINANCIAL LP10 percent owner | Sell | 1,033 | $4.67 |
| Jul 13, 2026 | HRT FINANCIAL LP10 percent owner | Buy | 8,266 | $3.38 |
| Jul 13, 2026 | HRT FINANCIAL LP10 percent owner | Buy | 731 | $3.11 |
| Jul 9, 2026 | HRT FINANCIAL LP10 percent owner | Sell | 18,531 | $3.52 |
| Jul 9, 2026 | HRT FINANCIAL LP10 percent owner | Sell | 10,580 | $3.33 |
| Jul 7, 2026 | HRT FINANCIAL LP10 percent owner | Buy | 7,851 | $3.54 |
| Jul 7, 2026 | HRT FINANCIAL LP10 percent owner | Sell | 9,022 | $3.51 |
| Jul 2, 2026 | HRT FINANCIAL LP10 percent owner | Buy | 3,959 | $3.30 |
| Jul 1, 2026 | HRT FINANCIAL LP10 percent owner | Buy | 6,755 | $3.23 |
| Jul 1, 2026 | HRT FINANCIAL LP10 percent owner | Buy | 25,836 | $3.44 |
| Aug 13, 2025 | Richards Steven Mdirector | Grant | 29,240 | — |
| Aug 12, 2025 | Tung Josephdirector | Grant | 29,240 | — |
| Aug 12, 2025 | Nabyt Olehdirector | Grant | 29,240 | — |
| Aug 12, 2025 | Scorsis Georgedirector | Grant | 29,240 | — |
Source: SHPH SEC Form 4 filings, latest Jul 15, 2026. For informational purposes only — not investment advice.
See the full SHPH insider & 13F page →Shuttle Pharmaceuticals Holdings, Inc. company profile
Overview
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) is a clinical-stage biopharmaceutical company founded in 2012 and headquartered in Rockville, Maryland. The company went public in August 2022 and focuses on developing specialized cancer treatments that enhance the effectiveness of radiation therapy. Shuttle Pharmaceuticals operates through its subsidiary, Shuttle Pharmaceuticals, Inc., and is currently advancing two key drug candidates through clinical trials to address some of the most challenging cancer types including brain tumors, sarcomas, and pancreatic cancer.
Business
Shuttle Pharmaceuticals operates in the specialized oncology drug development sector, specifically focusing on radiation sensitizers - a niche but critical area of cancer treatment. Radiation therapy is one of the primary treatment modalities for cancer, used in approximately 50% of all cancer cases. However, many tumors develop resistance to radiation or exist in environments where radiation is less effective. This is where radiation sensitizers come into play - they are drugs designed to make cancer cells more vulnerable to radiation damage while potentially sparing healthy tissue. The company's pipeline consists of two main drug candidates. Ropidoxuridine is an oral halogenated pyrimidine compound being developed to treat patients with brain tumors and soft tissue sarcomas. This drug works by incorporating into the DNA of rapidly dividing cancer cells, making them more susceptible to radiation-induced damage. Doranidazole is an injectable hypoxic cell radiation sensitizer targeting pancreatic, lung, and liver cancers. Hypoxic cells are cancer cells that exist in low-oxygen environments within tumors, making them particularly resistant to radiation therapy. Doranidazole specifically targets these hard-to-treat cancer cells. Both drug candidates represent the company's entire revenue-generating potential, as Shuttle Pharmaceuticals is a pure-play clinical-stage company with no commercial products currently generating meaningful revenue.
Revenue model
As a clinical-stage biopharmaceutical company, Shuttle Pharmaceuticals does not yet generate meaningful revenue from product sales. The company's minimal revenue of $5,748 in Q4 2024 likely represents research grants, licensing fees, or other non-core activities. The company's business model is built on the premise of developing its drug candidates through clinical trials, obtaining regulatory approval, and then either commercializing the drugs directly or licensing them to larger pharmaceutical companies. The company's primary funding comes from equity financing, as evidenced by its public offering in 2022. Like most clinical-stage biotech companies, Shuttle operates at a loss while investing heavily in research and development, clinical trials, and regulatory processes. The company's path to profitability depends on successfully advancing its drug candidates through Phase I, II, and III clinical trials, obtaining FDA approval, and then generating revenue through product sales or licensing agreements. Several factors could significantly impact the company's margins and financial success. Positive clinical trial results would likely increase the company's valuation and ability to secure additional funding or licensing deals. Conversely, negative trial results or regulatory setbacks could severely impact the company's prospects. The competitive landscape in oncology is intense, with major pharmaceutical companies and other biotech firms developing competing radiation sensitizers and alternative cancer treatments. Additionally, the company's burn rate and ability to secure continued funding will be critical, as clinical trials are expensive and time-consuming, often requiring years and tens of millions of dollars to complete.
Competitive moat
Shuttle Pharmaceuticals operates in a highly competitive and risky industry with limited sustainable competitive advantages. The company's primary moat lies in its specialized focus on radiation sensitizers and its intellectual property around its two drug candidates. However, this moat is relatively narrow and unproven. The company's competitive position is vulnerable for several reasons. First, as a clinical-stage company, Shuttle has not yet proven that its drugs are effective or safe in humans, making any competitive advantage theoretical. Second, the radiation sensitizer market, while specialized, is not immune to competition from larger pharmaceutical companies with significantly greater resources. Major oncology players like Roche, Bristol Myers Squibb, and Merck have the financial capacity to develop competing products or acquire promising smaller companies like Shuttle. The company's intellectual property portfolio around Ropidoxuridine and Doranidazole provides some protection, but patents in the pharmaceutical industry can be challenged, worked around, or may have limited remaining life. Additionally, the oncology field is rapidly evolving with new treatment modalities like immunotherapy, CAR-T cell therapy, and precision medicine potentially offering alternative approaches that could bypass the need for radiation sensitizers altogether. The most significant threat to Shuttle's position comes from the inherent risks of drug development. Clinical trials have high failure rates, and even promising early-stage results do not guarantee regulatory approval or commercial success. The company's narrow focus on just two drug candidates also means that failure of either program could be catastrophic for the business.
Risks & safety
Shuttle Pharmaceuticals presents significant financial risks with a very limited margin of safety for investors. • Cash burn and solvency: The company burned $7.3 million in cash from operations in FY 2024, with quarterly burn rates of approximately $2.5 million in Q1 2025. With only $4.5 million in cash as of Q1 2025, the company has less than two quarters of runway at current burn rates. • Debt and liquidity: Current ratio of 2.78 indicates adequate short-term liquidity, but the company's debt-to-equity ratio of 0.34 shows some leverage. The quick ratio of 2.78 suggests good liquidity position in the near term. • Valuation concerns: Trading at 1.19x book value with negative earnings makes traditional valuation metrics difficult to apply. The company's $2 million market cap represents extreme small-cap risk. • Financial deterioration: Net losses have increased from $3.0 million in 2022 to $9.1 million in 2024, showing accelerating cash burn as clinical programs advance. • Going concern risk: With minimal cash runway and no revenue generation, the company faces immediate financing needs to continue operations.
Recent development
Based on available financial data, Shuttle Pharmaceuticals has been advancing its clinical programs while managing severe cash constraints. The company's development activities appear focused on progressing both Ropidoxuridine and Doranidazole through their respective clinical trials, though specific trial results and milestones are not detailed in the financial statements. The company's cash position has deteriorated significantly since going public, falling from over $8.4 million at the end of 2022 to just $4.5 million by Q1 2025. This decline reflects the substantial costs associated with conducting clinical trials for both drug candidates. The increasing net losses from $3.0 million in 2022 to $9.1 million in 2024 suggest that clinical activities have intensified, likely indicating progression into more expensive later-stage trials or expansion of trial populations. The minimal revenue recognition of $5,748 in Q4 2024 suggests the company may have entered into small research collaborations or received milestone payments, though these amounts are not material to the overall business. The company's strategic focus appears to remain on advancing its core drug candidates rather than diversifying into other revenue streams or business development activities.
SHPH company profile · for informational purposes only — not investment advice.
Track SHPH with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free